{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T19:33:15Z","timestamp":1783625595119,"version":"3.55.0"},"reference-count":12,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2020,12,31]],"date-time":"2020-12-31T00:00:00Z","timestamp":1609372800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Salvage options for patients with relapsed B-cell acute lymphoblastic leukemia (B-ALL) include inotuzumab ozogamicin (InO), a recombinant, humanized anti-CD22 monoclonal antibody conjugated to the cytotoxic antibiotic calicheamicin. However, the benefit of InO in patients with dim CD22 expression remains unclear. We present a case of a patient with B-ALL who responded to InO despite only dim surface expression of CD22 by flow cytometry, achieving a survival benefit concordant with that reported in the literature and maintaining a good quality of life as a transfusion-independent outpatient. Our observation has broad relevance to clinicians who manage patients with B-ALL who are candidates for InO.<\/jats:p>","DOI":"10.3390\/curroncol28010027","type":"journal-article","created":{"date-parts":[[2021,1,19]],"date-time":"2021-01-19T04:55:31Z","timestamp":1611032131000},"page":"252-259","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Reevaluating Patient Eligibility for Inotuzumab Ozogamicin Based on CD22 Expression: Is Dim Expression Sufficient?"],"prefix":"10.3390","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5017-1583","authenticated-orcid":false,"given":"Warren","family":"Fingrut","sequence":"first","affiliation":[{"name":"Faculty of Medicine, University of British Columbia, Vancouver, BC V6T 1Z4, Canada"},{"name":"Department of Hematology, St. Paul\u2019s Hospital, Providence Health Care, Vancouver, BC V6Z 1Y6, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy","family":"Davis","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of British Columbia, Vancouver, BC V6T 1Z4, Canada"},{"name":"Department of Hematology, St. Paul\u2019s Hospital, Providence Health Care, Vancouver, BC V6Z 1Y6, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"McGinnis","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of British Columbia, Vancouver, BC V6T 1Z4, Canada"},{"name":"Department of Pathology and Laboratory Medicine, Providence Health Care, Vancouver, BC V6Z 1Y6, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Dallas","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of British Columbia, Vancouver, BC V6T 1Z4, Canada"},{"name":"Department of Pathology and Laboratory Medicine, Providence Health Care, Vancouver, BC V6Z 1Y6, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khaled","family":"Ramadan","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of British Columbia, Vancouver, BC V6T 1Z4, Canada"},{"name":"Department of Hematology, St. Paul\u2019s Hospital, Providence Health Care, Vancouver, BC V6Z 1Y6, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayley","family":"Merkeley","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of British Columbia, Vancouver, BC V6T 1Z4, Canada"},{"name":"Department of Hematology, St. Paul\u2019s Hospital, Providence Health Care, Vancouver, BC V6Z 1Y6, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Leitch","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of British Columbia, Vancouver, BC V6T 1Z4, Canada"},{"name":"Department of Hematology, St. Paul\u2019s Hospital, Providence Health Care, Vancouver, BC V6Z 1Y6, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasser","family":"Abou Mourad","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of British Columbia, Vancouver, BC V6T 1Z4, Canada"},{"name":"Leukemia\/BMT Program of British Columbia, Vancouver General Hospital, Vancouver, BC V5Z 1M9, Canada"},{"name":"British Columbia Cancer Agency, Vancouver, BC V5Z 4E6, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan D.","family":"Cassaday","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Washington, Seattle, WA 98195, USA"},{"name":"Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 19024, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilla","family":"Ross","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of British Columbia, Vancouver, BC V6T 1Z4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chantal","family":"L\u00e9ger","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of British Columbia, Vancouver, BC V6T 1Z4, Canada"},{"name":"Department of Hematology, St. Paul\u2019s Hospital, Providence Health Care, Vancouver, BC V6Z 1Y6, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,12,31]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1182\/blood-2012-06-438002","article-title":"Anti-CD22\u2013chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia","volume":"121","author":"Haso","year":"2013","journal-title":"Blood"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1056\/NEJMoa1509277","article-title":"Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia","volume":"375","author":"Kantarjian","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1002\/cncr.32116","article-title":"Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study","volume":"125","author":"Kantarjian","year":"2019","journal-title":"Cancer"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1084\/jem.181.4.1581","article-title":"Identification of the ligand-binding domains of CD22, a member of the immunoglobulin superfamily that uniquely binds a sialic acid-dependent ligand","volume":"181","author":"Engel","year":"1995","journal-title":"J. Exp. Med."},{"key":"ref_5","first-page":"11","article-title":"Antibody-targeted chemotherapy of B-cell lymphoma using calicheamicin conjugated to murine or humanized antibody against CD22","volume":"54","author":"Popplewell","year":"2004","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1007\/s00262-009-0688-5","article-title":"Treatment of non-Hodgkin\u2019s lymphoma xenografts with the HB22.7 anti-CD22 monoclonal antibody and phosphatase inhibitors improves efficacy","volume":"58","author":"Pearson","year":"2009","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_7","unstructured":"Rev, E. (2020, October 10). Rabbit Anti-Human CD22 Monoclonal Antibody (Clone SP104). Spring Bioscience 1\u20132. Available online: https:\/\/www.diagomics.com\/media\/file\/4a\/19\/02e0b5be59d7281c3c9c9623b5bf.pdf."},{"key":"ref_8","first-page":"1272","article-title":"Inotuzumab Ozogamicin for Relapsed\/Refractory Acute Lymphoblastic Leukemia in the Global Phase 3 INO-VATE Trial: Efficacy and Safety By Baseline CD22 Expression Level","volume":"130","author":"Hagop","year":"2017","journal-title":"Blood"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1111\/bjh.14820","article-title":"Randomized, Phase 3 Trial of Inotuzumab Ozogamicin plus Rituximab versus Chemotherapy plus Rituximab for Relapsed\/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma","volume":"82","author":"Dang","year":"2018","journal-title":"Br. J. Haematol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1038\/sj.leu.2404866","article-title":"Therapeutic potential of CD22-specific antibody-targeted chemotherapy using inotuzumab ozogamicin (CMC-544) for the treatment of acute lymphoblastic leukemia","volume":"21","author":"Dougher","year":"2007","journal-title":"Leukemia"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"5452","DOI":"10.1182\/blood-2018-99-114170","article-title":"Successful Salvage with Inotuzumab Ozogamicin in Relapsed\/Refractory Lymphoid Blast Crisis of Chronic Myeloid Leukemia after Failure of Multiple Lines of Therapy Including Blinatumomab","volume":"132","author":"Mansurov","year":"2018","journal-title":"Blood"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1016\/j.bbmt.2019.04.020","article-title":"Outcomes of Allogeneic Stem Cell Transplantation after Inotuzumab Ozogamicin Treatment for Relapsed or Refractory Acute Lymphoblastic Leukemia","volume":"25","author":"Marks","year":"2019","journal-title":"Biol. Blood Marrow Transpl."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/28\/1\/27\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:48:43Z","timestamp":1760179723000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/28\/1\/27"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,31]]},"references-count":12,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,2]]}},"alternative-id":["curroncol28010027"],"URL":"https:\/\/doi.org\/10.3390\/curroncol28010027","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,31]]}}}